Gilead’s twice-yearly shot cut HIV infections by 96% in trial

Gilead’s twice-yearly shot cut HIV infections by 96% in trial


A pharmacist holds a vial of lenacapavir, the new HIV prevention injectable drug.

Nardus Engelbrecht | AP

Gilead‘s twice-yearly shot reduced HIV infections by 96% in a second large study, the company said Thursday.

The positive phase three trial data on Lenacapavir sets the stage for likely approval by the U.S. Food and Drug Administration for HIV prevention.

“Now that we have a comprehensive dataset across multiple study populations, Gilead will work urgently with regulatory, government, public health and community partners to ensure that, if approved, we can deliver twice-yearly lenacapavir for PrEP worldwide, for all those who want or need PrEP,” said Gilead CEO Daniel O’Day in a statement.

PrEP or, pre-exposure prophylaxis, is a medication taken to prevent getting HIV, according to the Centers for Disease Control and Prevention.

Gilead shares climbed about 3% in premarket trading Thursday.

The company said 99.9% of participants who received Lenacapavir did not acquire HIV, with two cases among 2,180 people. The trial included cisgender men, transgender men, transgender women and gender non-binary people who have sex with partners assigned male at birth.

Subscribe to CNBC on YouTube.



Source

These innovative biotech stocks have a good chance of breaking out in 2025
Health

These innovative biotech stocks have a good chance of breaking out in 2025

Trends may be shifting in favor of biotech stocks in 2025 after several years of poor performance, but it would still be wise to place your bets carefully on some of the most innovative names. “We’re still optimistic on the outlook for biotech,” said Stacey Sears, senior vice president and portfolio manager at Emerald Advisors, […]

Read More
Danaher had a disappointing 2024. Its path to success next year goes through Wall Street
Health

Danaher had a disappointing 2024. Its path to success next year goes through Wall Street

Life sciences firm Danaher has certainly not been an easy stock to own this year. A wave of startups going public on Wall Street would go a long ways toward changing that. Year-to-date performance: down 0.1% Forward price-to-earnings multiple: 27.8 versus a five-year average of 28.8 Our rating: Buy-equivalent 1 Our price target: $305 a […]

Read More
FDA raises recall alert to highest level on Costco eggs over risk of severe illness or death due to salmonella
Health

FDA raises recall alert to highest level on Costco eggs over risk of severe illness or death due to salmonella

Eggs are displayed for sale inside a Costco store in Hawthorne, California, on January 26, 2023. Patrick T. Fallon | AFP | Getty Images Federal food regulators raised their alarm for recalled eggs sold from Costco stores over possible salmonella exposure, reclassifying the targeted product to their highest risk level. The FDA had previously announced on Nov. 27 that about […]

Read More